Events such as Russia's invasion of Ukraine in February 2022 have heightened global awareness of the potential for sudden market upheaval and the need for proactive measures to protect supply chains, including in the life sciences. But advancing an industrial policy on drugs requires several unique conditions-including a continued sense of acute threat among the US and its allies, ample public-sector funding, real-time data, industry buy-in, and bipartisan support in Congress-that are currently not present in the US.